Future in-depth characterization of ATIP3-associated intracellular mechanisms in normal and cancer cells are warranted to facilitate the design of new molecular therapies targeting a subpopulation of ATIP3-deficient breast cancer patients. Here, MTUS1 is linked to breast carcinoma.